Actually, there is a usually ignored fact that high-expensive monoclonal antibodies such as αPD-L1 temporarily inhibit the interaction of PD-L1 on the extracellular membrane of tumor cells and PD-1 on the surface of T cells, which has no influence on the intrinsic PD-L1 level of carcinoma cells. Here, CD274 is linked to carcinoma.